This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: DESTINY-Gastric03 - T-DXd Monotherapy and Combinations in Pts With Adv/Metastatic HER2+ Esophageal, Gastric, or GEJ Adenocarcinoma

125 views
October 2, 2024
Comments 0
Login to view comments. Click here to Login